Spots Global Cancer Trial Database for refractory multiple myeloma
Every month we try and update this database with for refractory multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | NCT04439227 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Adavosertib | 18 Years - | National Cancer Institute (NCI) | |
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01096342 | Refractory Mult... | dinaciclib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00482495 | Multiple Myelom... | bevacizumab gene expression... protein express... laboratory biom... | 18 Years - | Mayo Clinic | |
| Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00006890 | Multiple Myelom... | prednisone thalidomide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | NCT03731832 | Refractory Mult... | MLN9708 Pomalidomide 4 ... Dexamethasone Cyclophosphamid... | 18 Years - | GWT-TUD GmbH | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | NCT01301963 | Refractory Mult... | plerixafor filgrastim | 19 Years - | Case Comprehensive Cancer Center | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | NCT04439149 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | NCT00482846 | Mucositis Multiple Myelom... | Palifermin melphalan questionnaire a... autologous peri... quality-of-life... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | NCT03389347 | Plasma Cell Leu... Recurrent Multi... Refractory Mult... | Biospecimen Col... High Throughput... Laboratory Biom... | 18 Years - | University of Washington | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | NCT00243035 | Refractory Mult... Stage II Multip... Stage III Multi... | bortezomib tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | NCT04439318 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | NCT06232044 | Recurrent Multi... Refractory Mult... | Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00729118 | Multiple Myelom... Plasma Cell Neo... | lenalidomide vorinostat | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma | NCT03520985 | Refractory Mult... | Pomalidomide Dexamethasone | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| CI-994 in Treating Patients With Advanced Myeloma | NCT00005624 | Multiple Myelom... | CI-994 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | NCT00012350 | Multiple Myelom... | FTI | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | NCT00118170 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | sorafenib tosyl... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | NCT02192775 | Multiple Myelom... | MV-NIS | 18 Years - 75 Years | University of Arkansas | |
| Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004165 | Multiple Myelom... | filgrastim melphalan peripheral bloo... | - | Northwestern University | |
| Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00478075 | Multiple Myelom... | bortezomib immunologic tec... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | NCT06357988 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Echocardiograph... Radionuclide Im... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03702725 | Refractory Mult... Multiple Myelom... Multiple Myelom... | Ibrutinib Lenalidomide Dexamethasone | 18 Years - | Alliance Foundation Trials, LLC. | |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | NCT03770260 | Recurrent Multi... Refractory Mult... | Ixazomib Citrat... Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | NCT04439123 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Capivasertib | 18 Years - | National Cancer Institute (NCI) | |
| Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | NCT00006244 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | melphalan recombinant int... aldesleukin in vitro-treate... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment | NCT00389701 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Beta Alethine in Treating Patients With Myeloma | NCT00006466 | Multiple Myelom... Precancerous Co... | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma | NCT00567229 | Multiple Myelom... | rituximab lenalidomide microarray anal... flow cytometry laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT01074060 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim cyclophosphamid... autologous hema... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | NCT04519476 | Refractory Mult... | Selinexor Lenalidomide Methylprednisol... | 18 Years - | Oncotherapeutics | |
| S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | NCT00005834 | Multiple Myelom... | filgrastim cisplatin cyclophosphamid... dexamethasone etoposide thalidomide | 18 Years - | SWOG Cancer Research Network | |
| Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00568880 | Multiple Myelom... | bortezomib hydroxychloroqu... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | NCT00012350 | Multiple Myelom... | FTI | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TriPRIL CAR T Cells in Multiple Myeloma | NCT05020444 | Multiple Myelom... Multiple Myelom... Refractory Mult... | TriPRIL CAR T C... Cyclophosphamid... Fludarabine | 18 Years - | Massachusetts General Hospital | |
| Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma | NCT00335647 | Multiple Myelom... | fluphenazine hy... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | NCT00334932 | Multiple Myelom... | bortezomib melphalan pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | NCT00398515 | Refractory Mult... Stage II Multip... Stage III Multi... | lenalidomide temsirolimus pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | NCT01002248 | Multiple Myelom... | Perifosine Perifosine Plac... Bortezomib Dexamethasone | 18 Years - | AEterna Zentaris | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01564537 | Relapsed Multip... Refractory Mult... | Ixazomib Lenalidomide Dexamethasone Placebo | 18 Years - | Takeda | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | NCT04439357 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | NCT00118170 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | sorafenib tosyl... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | NCT00743288 | Multiple Myelom... | Melphalan Panobinostat | 18 Years - | Oncotherapeutics | |
| Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders | NCT00258258 | Multiple Myelom... | paricalcitol zoledronic acid | 18 Years - | Roswell Park Cancer Institute | |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | NCT04764942 | Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | NCT06421675 | Refractory Mult... | Elranatamab inj... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00445484 | Multiple Myelom... | pneumococcal po... lenalidomide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma | NCT00006013 | Multiple Myelom... | semaxanib | 18 Years - | Fox Chase Cancer Center | |
| Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00045136 | Multiple Myelom... | melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) | NCT06390826 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Sunitinib | 18 Years - | National Cancer Institute (NCI) | |
| PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00048230 | Multiple Myelom... | bortezomib | - | Millennium Pharmaceuticals, Inc. | |
| AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00022282 | Multiple Myelom... | shark cartilage... | 18 Years - | AEterna Zentaris | |
| Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) | NCT00293111 | Multiple Myelom... | SDX-101 (R-Etod... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | NCT04439175 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Taselisib | 18 Years - | National Cancer Institute (NCI) | |
| Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma | NCT00499577 | Multiple Myelom... | CMV pp65 peptid... hTERT I540/R572... pneumococcal po... survivin Sur1M2... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | NCT04439149 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | NCT06400225 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib | 18 Years - | National Cancer Institute (NCI) | |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | NCT01534143 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | pharmacological... tacrolimus sirolimus anti-thymocyte ... fludarabine pho... busulfan bortezomib allogeneic hema... laboratory biom... | 18 Years - 70 Years | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
